Onconova Therapeutics (ONTX) Prices 5M Share Offering at $4.20/sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Needham Starts NeoVolta (NEOV) at Buy
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
After-Hours Stock Movers 09/23: (PRGS) (COST) Higher; (ONTX) (NKE) (MTN) Lower (more...)
September 23, 2021 6:12 PM EDTAfter-Hours Stock Movers:
Onconova Therapeutics, Inc. (NASDAQ: ONTX) 12.3% LOWER; announced that it intends to offer and sell shares of its common stock in an underwritten public offering.
Onconova Therapeutics (ONTX) Announces Proposed Stock Offering; Size Not Disclosed
September 23, 2021 4:01 PM EDTOnconova Therapeutics, Inc. (NASDAQ: ONTX) (Onconova), a biopharmaceutical company focused on discovering and developing novel products to treat cancer, today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. All of the shares to be sold in the offering will be offered by Onconova. The offering is subject to market conditions and there can be no assurance as to whether or when the offering... More
Onconova Therapeutics (ONTX) Announces Encouraging Clinical Data Supporting the Anti-Cancer Activity of Rigosertib-Nivolumab Combination in Advanced KRAS+ Non-Small Cell Lung Cancer
September 22, 2021 8:03 AM EDTOnconova Therapeutics, Inc. (NASDAQ: ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced preliminary safety and efficacy data from an investigator-initiated Phase 1/2a trial of oral rigosertib plus the immune checkpoint inhibitor nivolumab in advanced KRAS mutated (KRAS+) non-small cell lung cancer (NSCLC). The data, which are being featured in a presentation at the... More
